VJOncology is committed to improving our service to you

ESMO 2019 | BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer

VJOncology is committed to improving our service to you

Véronique Dieras

Véronique Dieras, MD, Eugène Marquis Center, Rennes, France, discusses the BROCADE3 trial (NCT02163694). This trial is investigating the efficacy and tolerability of veliparib vs. a placebo in combination with carboplatin and paclitaxel in HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter